Bellerophon Receives Approval to Commence Phase 2 Trial in PH-COPD
-- Trial expected to commence in third quarter; Results to be reported by year end 2016 -- -- Previous data supporting testing long-term benefits of pulsed inhaled nitric oxide (iNO) reported in...
View ArticleTobira Therapeutics Announces Clinically and Statistically Significant...
(Source: Tobira Therapeutics Inc) --Company Plans to Initiate Phase 3 Study in 2017 Based on Cenicriviroc Meeting Potentially Registrational NASH Fibrosis Endpoint-- --No Difference Seen in Primary...
View ArticleAlnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a...
(Source: Alnylam Pharmaceuticals Inc) 07.25.2016 - Fitusiran Achieves Median Estimated Annualized Bleeding Rate of Zero in Patients without Inhibitors - - In Initial Low Dose Cohort of Patients with...
View ArticleMediciNova Receives Notice of Allowance for New Patent Covering MN-001 and...
LA JOLLA, Calif., July 24, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...
View ArticleTobira Therapeutics Announces Clinically and Statistically Significant...
Tobira Therapeutics Announces Clinically and Statistically Significant Improvement in Liver Fibrosis From Phase 2b CENTAUR NASH Trial at One Year --Company Plans to Initiate Phase 3 Study in 2017 Based...
View ArticleAlnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a...
Alnylam Announces New Positive Interim Phase 1 Study Results for Fitusiran, a Once-Monthly, Subcutaneous, Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia and...
View ArticleAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and...
(Source: Astellas Pharma Inc) 037edda6-802a-4538-9bba-d2b86840b593.pdf Astellas and FibroGen Announce First Patient Treated in Phase 3 Studies and Positive Phase 2 Results of Roxadustat in Patients...
View ArticleAstellas and FibroGen Announce First Patient Treated in Phase 3 Studies and...
(Source: FibroGen Inc) TOKYO and SAN FRANCISCO, July 25, 2016 (GLOBE NEWSWIRE) -- Astellas Pharma Inc. (TSE:4503) ('Astellas') and FibroGen, Inc. (Nasdaq:FGEN) ('FibroGen'), today announced the dosing...
View ArticleCerecor Announces Research Grant from the Department of Defense to Study...
(Source: Cerecor Inc) BALTIMORE--(BUSINESS WIRE)--Jul. 25, 2016-- Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of...
View ArticleCHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of...
CHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of Highly Active and Progressive Disease in Adult Patients with Rheumatoid Arthritis not Previously Treated with Methotrexate in...
View ArticleCHMP Issues Positive Opinion for ORENCIA® (abatacept) in the Treatment of...
(Source: Bristol-Myers Squibb Company) PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the...
View ArticleCynapsus Therapeutics Announces Positive Phase 3 Dose Titration Phase Results...
(Source: Cynapsus Therapeutics Inc) -- Webcast with accompanying slides to discuss these findings tomorrow at 7:30 a.m. Eastern time Top-line CTH-300 results expected in late Q3 or early Q4 -- TORONTO,...
View ArticleBlue-Blocking Glasses May Help Treat Bipolar Disorder, Promote Sleep
If you have bipolar disorder, depression or trouble sleeping, it may help to wear amber-tinted glasses at night, new research suggests. These orange shades block blue light, which the body uses to...
View ArticleCSL Behring Presents Phase III Data for IDELVION® for Hemophilia B at the...
(Source: CSL Behring LLC) ORLANDO, Fla. - 26 July 2016 New analyses from global PROLONG-9FP clinical development program show: Adult patients prolonged dosing interval to up to 21 days for routine...
View ArticleTokai Pharmaceuticals Announces Clinical Update (Tokai Pharmaceuticals Inc)
(Source: Tokai Pharmaceuticals Inc) Company to Discontinue Phase 3 ARMOR3-SV Trial of Galeterone in AR-V7 Positive mCRPC Tokai to Host Conference Call Today at 8:30 AM E.T. BOSTON--(BUSINESS...
View ArticleAddex ADX71441 Demonstrates Positive Results in Highly Translational...
(Source: Addex Therapeutics Ltd) Addex ADX71441 Demonstrates Positive Results in Highly Translational Preclinical Model of Spasticity. Geneva, Switzerland, 27 July 2016- Addex Therapeutics (SIX: ADXN)...
View ArticleMinerva Neurosciences, Inc. : Minerva Neurosciences Provides Update on...
(Source: Minerva Neurosciences Inc) Patient Recruitment Ongoing in Trials in Insomnia Disorder and Adjunctive Major Depressive Disorder WALTHAM, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Minerva...
View ArticleMinerva Neurosciences Provides Update on Clinical Development Program With...
WALTHAM, Mass., Sept. 24, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
View ArticleErgomed’s Co-Development Partner Ferrer Initiates Phase IIa Study of...
(Source: Ergomed plc) Guildford, UK - 14 July 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical...
View ArticleCo-development partner news (Ergomed plc)
(Source: Ergomed plc) Ergomed's Co-Development Partner Ferrer Initiates Phase IIa Study of Lorediplon in Patients with Insomnia Guildford, UK - 14 July 2015: Ergomed plc, (LSE: ERGO or 'Ergomed') a...
View Article